Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies-Reference-Cited by-同舟云学术

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

Published:2017-08-01 Issue:21 Volume:23 Page:6411-6420
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Aftimos Philippe,Rolfo Christian,Rottey Sylvie,Offner Fritz,Bron Dominique,Maerevoet Marie,Soria Jean-Charles,Moshir Mahan,Dreier Torsten,Van Rompaey Luc,Michot Jean-Marie,Silence Karen,Hultberg Anna,Gandini Domenica,de Haard Hans,Ribrag Vincent,Peeters Marc,Thibault Alain,Leupin Nicolas,Awada Ahmad

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma;Cancer Discovery;2024-04-04

2. ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study;European Journal of Nuclear Medicine and Molecular Imaging;2024-03-14

3. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study;The Lancet Haematology;2023-11

4. Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment;The Lancet Haematology;2023-11

5. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling;Frontiers in Oncology;2023-10-02